

## **ASX ANNOUNCEMENT**

### **ADMEDUS DIRECTOR STEPS DOWN**

- Peter Turvey steps down from board

#### **Brisbane, Australia 8 February 2016**

Admedus Limited (ASX: AHZ) today announced that Mr Peter Turvey has resigned as an independent Non-Executive Director due to other commitments. Mr Turvey has served on the Admedus board for the past 3 years and was head of the Audit and Risk Committee.

“We thank Peter for his invaluable contribution over the past 3 years. During this period Admedus has grown through its R&D programs, approval of the lead regenerative product CardioCel® and the progression of the immunotherapies program into the clinic” stated Admedus CEO Mr Lee Rodne

Mr Turvey’s resignation is effective immediately.

Follow us:

Twitter: @Admedus

Facebook: [www.facebook.com/pages/Admedus](http://www.facebook.com/pages/Admedus)

#### **For more information, please contact:**

Dr Julian Chick | Chief Operating Officer | Admedus Limited

Tel: +61 (0)8 9266 0100

#### **Media:**

Shevaun Cooper | PR Manager | Admedus Limited

Tel: +61 (0) 417 985 599 | Email: [scooper@admedus.com](mailto:scooper@admedus.com)

#### **Media Europe**

FTI Consulting

Simon Conway / Victoria Foster Mitchell

Tel: +44 (0) 20 3727 1000

[admedus@fticonsulting.com](mailto:admedus@fticonsulting.com)

#### **US Investor**

Rx Communications Group, LLC

Melody A. Carey

+1 917 322 2571

[mcarey@rxir.com](mailto:mcarey@rxir.com)

## **About Admedus Limited**

Admedus (ASX: AHZ) is a specialist healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

Admedus has commercialised its innovative tissue engineering technology for regenerative medicine in four continents. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.

Further information on the company can be found on [www.admedus.com](http://www.admedus.com)